Akari rises on rare pediatric disease designation for blood disorder drug
10/11/2022 13:36
** Akari Therapeutics Plc's shares AKTX.O rise 7.8% to
$0.55 before the bell
** U.S. FDA grants rare pediatric disease designation to
AKTX's experimental drug to treat rare blood disorder associated
with bone marrow transplant urn:newsml:reuters.com:*:nGNX9hrt9z
** Designation to enable speedy review process during
marketing approval
** Up to Wednesday's close, stock had fallen ~66% YTD
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))